Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asterasys CoXKRX:450950 -4.29%23 FCF Margin % is 14.03% as of Jun. 2026, which is 53% above its 10-year median of 9.19. GuruFocus rates XKRX:450950 with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Asterasys Co ranks worse than 52.77% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Asterasys Co's Free Cash Flow for the
three
months ended in Jun. 2026 was ₩1,574 Mil. Asterasys Co's Revenue for the
three
months ended in Jun. 2026 was ₩11,222 Mil. Therefore, Asterasys Co's FCF Margin % for the quarter that ended in Jun. 2026 was 14.03%.
The historical rank and industry rank for Asterasys Co's FCF Margin % or its related term are showing as below:
XKRX:450950'
s FCF Margin % Range Over the Past 10 Years
Min: -1.35 Med: 9.19 Max: 16.86
Current: -1.35
During the past 5 years, the highest FCF Margin % of Asterasys Co was 16.86%. The lowest was -1.35%. And the median was 9.19%.
XKRX:450950's FCF Margin % is ranked worse than 52.77% of 813
companies
in the Medical Devices & Instruments industry
Industry Median: -0.52
vs XKRX:450950: -1.35
The historical data trend for Asterasys Co's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:450950 vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Asterasys Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asterasys Co FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Asterasys Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Asterasys Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asterasys Co (XKRX:450950) has a FCF Margin % of 14.03% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Asterasys Co and its competitors. This is 53% above median its historical median of 9.19. According to the industry distribution chart, Asterasys Co ranks #429 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 52.8%.
Is Asterasys Co's FCF Margin % too high?
Asterasys Co's current FCF Margin % of 14.03% is 53% above median its 10-year median of 9.19. Based on the distribution chart, Asterasys Co ranks #429 out of 813 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Asterasys Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Asterasys Co's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Asterasys Co ranks #429 out of 813 companies for FCF Margin %. This places Asterasys Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Asterasys Co and its competitors. Asterasys Co's current FCF Margin % is 14.03%, which is 53% above median its own 10-year median of 9.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asterasys Co stock overvalued right now?
Asterasys Co (XKRX:450950) has a current FCF Margin % of 14.03%. The current FCF Margin % is 14.03%, which is 53% above median its 10-year median of 9.19. Asterasys Co's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Asterasys Co (XKRX:450950), the current FCF Margin % is 14.03% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asterasys Co Ltd is a professional healthcare and biomedical corporation based in Korea. It is engaged in the Manufacture of electro-diagnostic and electro-therapeutic apparatuses featuring body composition analyzers such as the InBalance series and HIFU systems such as the Liftera series, it provides total solutions with healthcare, skincare, and IoT-oriented services that can connect with its product portfolio.
23GF Score
Get the complete analysis for XKRX:450950
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:450950 has been successfully added to your 
